Company / Total Assets
Arcadia Biosciences, Inc. Total Assets History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Assets
$6.5M
FY2025
5-year range
$6.5M / $43.9M
FY2021-FY2025
Trend
-51.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Total Assets has declined for 5 consecutive years, from $47M in FY2020 to $7M in FY2025.
Based on SEC 10-K filings.
$7M in FY2025 with a 5-year CAGR of -32.7%.
Declined from $20M to $7M over the past 2 years.
Total Assets over time
Growth rates
- 3-Year CAGR
- -39.1%
- 5-Year CAGR
- -32.7%
- 10-Year CAGR
- -
Key checks
Key Insights
- Arcadia Biosciences, Inc.'s total assets has declined for 5 consecutive years.
- 5-year CAGR of -32.7%, indicating a declining trend.
- In FY2025, total assets decreased 51.6% year-over-year.
- Peak total assets was recorded in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 7.60 (safe zone, above 2.9 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $6.5M | -51.6% |
| FY2024 | $13.5M | -31.4% |
| FY2023 | $19.7M | -31.9% |
| FY2022 | $28.9M | -34.1% |
| FY2021 | $43.9M | -7.2% |
| FY2020 | $47.3M | +45.4% |
| FY2019 | $32.6M | +35.6% |
| FY2018 | $24.0M | +45.0% |
| FY2017 | $16.6M | -70.7% |
| FY2016 | $56.6M | -23.8% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026